Leerink Partnrs Has Pessimistic View of CNTA FY2025 Earnings

Key Points

• Leerink Partners has lowered its earnings per share (EPS) estimate for Centessa Pharmaceuticals for FY2025 to ($1.37), a decrease from its previous estimate of ($1.34).
• Centessa Pharmaceuticals' current consensus estimate for full-year earnings is (1.60) EPS, with additional negative projections for subsequent fiscal years.
• The stock is rated as a Moderate Buy by analysts, with an average price target of $28.10, despite a reported quarterly EPS of ($0.38), which missed estimates.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Centessa Pharmaceuticals in a research report issued on Tuesday, August 12th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of ($1.37) for the year, down from their prior estimate of ($1.34). The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals' Q4 2025 earnings at ($0.40) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($1.86) EPS and FY2029 earnings at $0.77 EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03).

Other equities research analysts also recently issued reports about the company. Oppenheimer began coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price for the company. Chardan Capital restated a "buy" rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a "buy" rating and a $35.00 target price on the stock. Finally, Truist Financial began coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $30.00 price target for the company. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $28.10.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock traded down $0.46 on Friday, hitting $17.59. The company had a trading volume of 1,012,773 shares, compared to its average volume of 1,149,587. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $19.09. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. The company has a market cap of $2.36 billion, a PE ratio of -9.83 and a beta of 1.48. The business has a 50-day simple moving average of $14.88 and a 200-day simple moving average of $14.48.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after acquiring an additional 660 shares during the last quarter. HighMark Wealth Management LLC grew its stake in Centessa Pharmaceuticals by 0.6% in the second quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company's stock valued at $3,118,000 after purchasing an additional 1,500 shares in the last quarter. HighVista Strategies LLC increased its position in Centessa Pharmaceuticals by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 40,684 shares of the company's stock worth $535,000 after purchasing an additional 1,664 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $31,000. Finally, Trexquant Investment LP lifted its holdings in shares of Centessa Pharmaceuticals by 1.1% during the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company's stock valued at $3,796,000 after buying an additional 2,810 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Insiders Place Their Bets

In other news, insider Mario Alberto Accardi sold 8,322 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $15.23, for a total value of $126,744.06. Following the completion of the sale, the insider directly owned 208,163 shares of the company's stock, valued at $3,170,322.49. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $15.56, for a total transaction of $155,600.00. Following the sale, the insider owned 122,279 shares of the company's stock, valued at approximately $1,902,661.24. This represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 236,322 shares of company stock valued at $3,300,064 in the last 90 days. Insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.